Huge quarterly!!
Off the top:
Revenue up 237% overall from last quarter.
Europe division up 1600% on pervious quarter. (This shows a huge increase in demand)
Canada division up 340% compared to Q1 2020.
18.6m Cash.
Once shareholders approve the acquisition of Halucenex life scieneces we will be the ONLY company on the ASX to be a 100% owned psychedelic company. Psychedelics are the next big thing imo, industry is steaming ahead.
US DUAL LISTING ON OTC MARKET IS "Imminent"
- Keep in mind, MindMed went from 60c (180m MC) to $5 (2b MC) once listed on the OTC US market and has now just listed on the NASDAQ too.
The halucenex synethic psilocybin clinical phase 2 trials progressing well.
Overall very happy with where this company is heading in terms of growth and demand.
Should be an interesting day of trading.
Ann: Quarterly Update & Appendix 4C, page-10
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)